Ocular Therapeutix, Inc.
HealthcareNASDAQ:OCUL · NASDAQ Global Market
+$0.24 today
Vol 2.69M · Avg 3.04M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-40.6%
avg 113.0%
ROIC
-35.5%
avg -63.2%
ROA
-32.9%
avg -56.0%
Analysis
ROA is currently the strongest return metric at -32.9% versus its period average of -56.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Pravin U. Dugel | Executive Chairman, President & Chief Executive Officer | $1.77M | — | 62 | $694,811.00 | 0.32% |
Donald Notman Jr. | CFO, COO & Principal Accounting Officer (Leave of Absence) | $969,180.00 | — | — | $366,356.00 | 0.17% |
Nadia K. Waheed | Chief Medical Officer | $935,795.00 | — | 49 | $300,079.00 | 0.14% |
Sanjay Nayak MBBS | Chief Strategy Officer | $845,653.00 | — | 56 | $328,795.00 | 0.15% |
Steve Meyers | Chief Commercial Officer | $808,678.00 | — | — | $217,628.00 | 0.10% |
Peter K. Kaiser | Chief Development Officer | $698,866.00 | — | 59 | $266,141.00 | 0.12% |
Jeffrey S. Heier | Chief Scientific Officer | $676,550.00 | — | 65 | $320,350.00 | 0.15% |
William S. Slattery Jr. | Vice President of Investor Relations | — | — | — | $320,350.00 | 0.15% |
Namrata Saroj | Chief Business Officer | — | — | 52 | $254,620.00 | 0.12% |
Peter K. Jarrett | Chief Technical Officer | — | — | 69 | $266,141.00 | 0.12% |
Art Ciociola | Chief Regulatory & Quality Officer | — | — | — | — | — |
Barry Rubenstein | Chief Human Resources Officer | — | — | — | — | — |
Chad Clatterbaugh | Chief of Staff | — | — | — | — | — |
David W. Robinson | Global Chief Commercial Officer | — | — | 67 | $136,000.00 | 0.06% |
Jason Robins | Senior VP of Finance, Interim CFO & Principal Accounting Officer | — | — | 49 | $0.00 | <0.01% |
Todd Anderman | Chief Legal Officer & Corporate Secretary | — | — | 44 | $197,650.00 | 0.09% |
William H. Ransone | Vice President of Global Sales & Marketing | — | — | — | $313,335.00 | 0.14% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$461,354.14
Sells
29
$3.46M
Net Sentiment
$2.99M
Net selling
Most Active
Kaiser Peter
5 transactions
1–10 of 30
Analysis
Insiders reported 1 buys worth $461,354.14 and 29 sells worth $3.46M over the last 12 months. That adds up to net selling of $2.99M. Kaiser Peter was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +56.8% (14yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +56.8% (14yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.44B
Liquidia Corporation
NASDAQ:LQDA
$6.33B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.75B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.47B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.40B
Galapagos N.V.
GLPG
$1.84B
Mesoblast Limited
NASDAQ:MESO
$1.79B
uniQure N.V.
NASDAQ:QURE
$1.74B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.47B
Who manages OCUL?
Ocular Therapeutix, Inc. (OCUL) lists 17 active executives. The top listed executive is Steve Meyers, Chief Commercial Officer.
Are OCUL insiders buying or selling?
Recent insider activity shows net buying of $98.84M.
Explore More
Continue the stock analysis
Jump to another research area for this company.